Regulation of Dipeptidyl Peptidase-4, its Substrate Chemokines, and Their Receptors in Adipose Tissue of ob/ob Mice

Abstract The physiological function of DPP-4 in proteolytic inactivation of incretins has been well established, however, there is limited information on the expression and the significance of DPP-4 in white adipose tissue with regard to obesity. The objective of the work was to reveal the expression and regulation of DPP-4 in adipocytes and compare the expression and activity of DPP-4 in white adipose tissue and several other organs such as the liver, muscle and kidney. We also investigated the gene expression levels of DPP-4 substrate chemokines, and their receptors in white adipose tissue. DPP-4 was mainly expressed in stromal vascular fraction (SVF), and downregulated in adipose tissue of ob/ob compared with C57BL6/J mice. Mimetic conditions of obese fat in vitro showed that differentiation of mouse primary preadipocytes into adipocytes was associated with marked downregulation of DPP-4 expression. Treatment with TNF-α or ROS even decreased DPP-4 expression in mouse primary adipocytes. Various DPP-4 substrate chemokines were expressed in white adipose tissue and regulated by obesity. The expression of receptors for DPP-4 substrate chemokines was markedly high and tightly regulated by obesity in white adipose tissue. Expression of DPP-4 was reduced in adipose tissues of ob/ob mice. Actions of several substrate chemokines might be potentiated by downregulation of DPP-4, synergistically with upregulation of chemokines and their receptors in adipose tissues of obese mice.

[1]  P. Mayer,et al.  Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes , 2016, Scientific Reports.

[2]  M. Kreft,et al.  Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes , 2016, Journal of diabetes research.

[3]  Matthew L Albert,et al.  Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy , 2015, Nature Immunology.

[4]  Vimal K. Narula,et al.  CXCR3 modulates obesity‐induced visceral adipose inflammation and systemic insulin resistance , 2014, Obesity.

[5]  A. Luster,et al.  Chemokines and chemokine receptors: positioning cells for host defense and immunity. , 2014, Annual review of immunology.

[6]  P. Scherer,et al.  Tracking adipogenesis during white adipose tissue development, expansion and regeneration , 2013, Nature Medicine.

[7]  Y. Higashimoto,et al.  Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor , 2013, Cardiovascular Diabetology.

[8]  S. Kaneko,et al.  CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status , 2012, Diabetes.

[9]  J. Kaufman,et al.  Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome , 2011, Diabetes.

[10]  R. Locksley,et al.  Eosinophils Sustain Adipose Alternatively Activated Macrophages Associated with Glucose Homeostasis , 2011, Science.

[11]  C. Faul,et al.  Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice , 2011, Journal of Lipid Research.

[12]  Xin Chen,et al.  The dimeric transmembrane domain of prolyl dipeptidase DPP‐IV contributes to its quaternary structure and enzymatic activities , 2010, Protein science : a publication of the Protein Society.

[13]  A. Avogaro,et al.  The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes , 2010, Diabetes Care.

[14]  G. Steinberg,et al.  Adipose tissue as an endocrine organ , 2010, Molecular and Cellular Endocrinology.

[15]  E. Maury,et al.  Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome , 2010, Molecular and Cellular Endocrinology.

[16]  C. Abbott,et al.  Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? , 2009, Trends in pharmacological sciences.

[17]  O. Cordero,et al.  On the origin of serum CD26 and its altered concentration in cancer patients , 2009, Cancer Immunology, Immunotherapy.

[18]  K. Kawazoe,et al.  Increased plasma dipeptidyl peptidase IV (DPP IV) activity and decreased DPP IV activity of visceral but not subcutaneous adipose tissue in impaired glucose tolerance rats induced by high-fat or high-sucrose diet. , 2009, Biological & pharmaceutical bulletin.

[19]  V. Hombach,et al.  T-lymphocyte Infiltration in Visceral Adipose Tissue: A Primary Event in Adipose Tissue Inflammation and the Development of Obesity-Mediated Insulin Resistance , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[20]  Katerina Akassoglou,et al.  NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α , 2008, Nature.

[21]  A. Su,et al.  Expression analysis of G Protein-Coupled Receptors in mouse macrophages , 2008, Immunome research.

[22]  G. Koh,et al.  Membrane proteomic analysis of human mesenchymal stromal cells during adipogenesis , 2007, Proteomics.

[23]  B. Ahrén.  Dipeptidyl Peptidase-4 Inhibitors , 2007, Diabetes Care.

[24]  Hong Wang,et al.  Adiponectin Secretion Is Regulated by SIRT1 and the Endoplasmic Reticulum Oxidoreductase Ero1-Lα , 2007, Molecular and Cellular Biology.

[25]  M. Matsuda,et al.  Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation , 2007, Diabetes.

[26]  Leif E. Peterson,et al.  T-Cell Accumulation and Regulated on Activation, Normal T Cell Expressed and Secreted Upregulation in Adipose Tissue in Obesity , 2007, Circulation.

[27]  A. Saltiel,et al.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization. , 2007, The Journal of clinical investigation.

[28]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[29]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[30]  Ärztlicher Direktor,et al.  Endothelial Catabolism of Extracellular Adenosine during Hypoxia : Role of Surface Adenosine Deaminase and CD 26 , 2008 .

[31]  R. Kitazawa,et al.  MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.

[32]  R. Leibel,et al.  CCR2 modulates inflammatory and metabolic effects of high-fat feeding. , 2006, The Journal of clinical investigation.

[33]  S. Coppack,et al.  Adipose tissue changes in obesity. , 2005, Biochemical Society transactions.

[34]  C. Herling,et al.  Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. , 2005, The American journal of pathology.

[35]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[36]  J. Lenhard,et al.  Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. , 2004, Biochemical and biophysical research communications.

[37]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[38]  B. Lindner,et al.  Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I‐TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine , 2002, Journal of leukocyte biology.

[39]  M. Parmentier,et al.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.

[40]  G. McCaughan,et al.  CD26: A Multifunctional Integral Membrane and Secreted Protein of Activated Lymphocytes , 2001, Scandinavian journal of immunology.

[41]  P. Proost,et al.  Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. , 2000, Blood.

[42]  O. Cordero,et al.  Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. , 2000, Cytokine.

[43]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[44]  P. Allavena,et al.  Human Macrophage–derived Chemokine (mdc), a Novel Chemoattractant for Monocytes, Monocyte-derived Dendritic Cells, and Natural Killer Cells , 1997 .

[45]  T. Yamabe,et al.  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL‐2, IL‐12 or IL‐15 , 1997, Immunology.

[46]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[47]  J. Gum,et al.  Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. , 1995, The Biochemical journal.

[48]  R. Ardaillou,et al.  Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. , 1993, Immunology.

[49]  T. Funahashi,et al.  The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. , 2011, Journal of atherosclerosis and thrombosis.

[50]  Bonnie J. Ahr.  Dipeptidyl Peptidase-4 Inhibitors Clinical data and clinical implications , 2007 .

[51]  Nanxin Li,et al.  Oxidative stress and gene expression: The AP‐1 and NF‐κB connections , 2001 .

[52]  P. Kapahi,et al.  Oxidative stress and gene expression: the AP-1 and NF-kappaB connections. , 2001, BioFactors.

[53]  P. Proost,et al.  The role of CD26/DPP IV in chemokine processing. , 1999, Chemical immunology.

[54]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.